How do I interpret an HbA1c trend across three draws?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere.

I would like to know the limits of what can be inferred from this.

What I am trying to avoid is over-reading a single result, which I have done before.

What can I legitimately conclude from this figure?

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Research-use compounds are not approved for human use, and no panel makes that safer.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Put another way, a sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

Decide the action for each result before you order the test.

The short version: a small, well-chosen panel with a baseline beats a large one without.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

SELECT reported a hazard ratio of 0.80 (95% CI 0.72–0.90) for the primary composite major adverse cardiovascular event endpoint with semaglutide 2.4 mg in overweight or obese adults with established cardiovascular disease and without diabetes[1].

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Keep the full report, not the number. You will need the units and the interval later.

edited 19 Sept 2024 by cold_lane — fixed an arithmetic slip in the third paragraph